耐马粉通过调节炎症,葡萄糖和脂质代谢以及肠道微生物环境来改善2型糖尿病
Xiangyun Liu1, Qianyun Ma2, Yaxing Feng3
1College of Food Science and Technology, Hebei Agricultural University, 289th Lingyusi Street, Lianchi District, Baoding 071000, China; College of Chemical Engineering and Biotechnology, Xing Tai University, 88th Quanbei East Street, Xiangdu District, Xingtai 054001, China.
耐马粉3 (PRS3) 在2型糖尿病小鼠模型中改善了葡萄糖耐受性和胰岛素耐药性. 此外,PRS3还调节了肠道微生物群,减少了炎症和氧化应激.
科学领域:
- 代谢性疾病是一种代谢性疾病.
- 微生物学 微生物学
- 营养科学 营养科学
背景情况:
- 2型糖尿病 (T2DM) 是一个日益严重的全球健康问题.
- 功能障碍的葡萄糖代谢,胰岛素耐药性和改变的肠道微生物群是T2DM的特征.
- 积极寻求针对代谢途径和肠道微生物群的治疗策略.
研究的目的:
- 为了研究土豆耐性粉3 (PRS3) 对2型糖尿病 (T2DM) 鼠标模型的影响.
- 阐明PRS3潜在降血糖效应背后的机制.
- 评估PRS3对代谢参数,炎症,氧化应激和肠道微生物群组成的影响.
主要方法:
- 建立了2型糖尿病小鼠模型.
- 与土豆耐性粉3 (PRS3) 的干预.
- 评估葡萄糖耐受性,胰岛素耐药性,脂质代谢,氧化应激标志物,炎症因素以及胰腺/肝脏组织病理学.
- 使用测序分析便短链脂肪酸含量和肠道微生物群组成 (系和物种水平).
主要成果:
- 在T2DM小鼠中,PRS3显著改善了葡萄糖耐受性和胰岛素敏感性.
- PRS3缓解了异常的脂质代谢,减少了氧化应激,并抑制了肝脏和胰腺炎症.
- 干预PRS3导致便短链脂肪酸的增加和肠道微生物群组成的显著改变,包括关键细菌类和物种的变化.
结论:
- 抗马粉3 (PRS3) 证明了对2型糖尿病的显著治疗潜力.
- 通过改善代谢参数,减少炎症和氧化应激,并有利地调节肠道微生物群,PRS3发挥了有益的影响.
- 这些发现为PRS3作为T2DM管理的饮食干预提供了机制基础.
更多相关视频
08:47Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
Published on: December 7, 2017
08:32Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Diabetes Mellitus: Type 2 and Gestational
Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
